Short­ly af­ter pump­ing $50M in­to In­di­ana site, Catal­ent will hire up to 600 new em­ploy­ees

Mod­er­na’s vac­cine man­u­fac­tur­ing part­ner Catal­ent has spent all of 2021 cap­i­tal­iz­ing on the mas­sive de­mand for vac­cine man­u­fac­tur­ing and ex­pand­ing its op­er­a­tions through merg­ers, ac­qui­si­tions and site build outs. Now, it’s time to staff those fa­cil­i­ties.

The Som­er­set, NJ man­u­fac­tur­er had two job fairs last week at the Mon­roe Coun­ty Con­ven­tion Cen­ter in hopes of staffing its site in Bloom­ing­ton, IN. The com­pa­ny is hir­ing for jobs rang­ing from di­rec­tor to tech­ni­cians, and es­pe­cial­ly en­try-lev­el roles in man­u­fac­tur­ing and the ware­house. Catal­ent will try to hire be­tween 500 and 600 em­ploy­ees.

Se­nior di­rec­tor of hu­man re­sources Ar­turo Lopez told The Her­ald-Times that the com­pa­ny is in part up­ping pro­duc­tion be­cause of Covid-19 vac­cines be­cause of de­mand, and the com­pa­ny ex­pects to keep up for both ini­tial shots and boost­ers. Catal­ent has in­vest­ed more than $250 mil­lion in Mon­roe Coun­ty since 2019, and that num­ber is ex­pect­ed to grow. The lo­cal site cur­rent­ly has 3,500 em­ploy­ees.

In Sep­tem­ber 2020, Catal­ent ac­quired the 23,000 square-foot site from AB BioTech­nolo­gies and out­fit­ted it in time for op­er­a­tions to start at the be­gin­ning of this year. Around 40 peo­ple were hired to staff the new site, which fea­tured a small-scale fill­ing line, used pri­mar­i­ly for ear­ly phase clin­i­cal tri­als.

Catal­ent ex­pand­ed its deal with Mod­er­na in April to churn out dou­ble the num­ber of fin­ished vials of the vac­cine to 400 vials per minute at the Bloom­ing­ton site. Mod­er­na will have a ded­i­cat­ed fill­ing line in Bloom­ing­ton through 2023.

En­try-lev­el pay starts at $18 per hour, and em­ploy­ees are set to get ben­e­fits from the start. The Her­ald-Times re­port­ed that the state’s un­em­ploy­ment rate was down to 4.1% in Au­gust, rough­ly 3.2% low­er than what it was in Au­gust 2020.

There’s been a bat­tle for top tal­ent in phar­ma­ceu­ti­cal man­u­fac­tur­ing as of late, as com­pa­nies con­tin­ue to quick­ly ramp up sup­ply agree­ments and ex­pand op­er­a­tions, large­ly due to the mas­sive in­crease in de­mand for bi­o­log­ics and vac­cines. In the last year, Catal­ent has ex­pand­ed at sites in Madi­son, WI and Anag­ni, Italy.

Catal­ent’s earn­ings have in­creased 159% in the past year to $585 mil­lion. The com­pa­ny’s stock price this year is up 27%.

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The slate of products we’re offering here at Endpoints is continuing to grow, and it’s not just limited to editorial. If you haven’t, do visit your reader profile to see if there are any other weekly newsletters you’re interested in — as each comes with its own exclusive content. And don’t miss the publisher’s note from Arsalan Arif on Endpoints Studio, our latest avenue for advertising on Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Usama Malik

Ex-Im­munomedics CFO charged with in­sid­er trad­ing, faces up to 20 years in prison af­ter al­leged­ly tip­ping off girl­friend and rel­a­tives of a PhI­II suc­cess

The former CFO of Immunomedics, who helped steer the company to its $21 billion buyout by Gilead last year, has been charged with insider trading, the Department of Justice announced Thursday.

Usama Malik tipped off his then-girlfriend and four others that a Phase III study for Trodelvy would be stopped early four days before Immunomedics publicly announced the result in April 2020, DoJ alleged in its complaint. The individuals then purchased Immunomedics shares, selling them after the news broke and Immunomedics’ stock price doubled.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Merck's new antiviral molnupiravir (Quality Stock Arts / Shutterstock)

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it, which has more than 30 mutations in the spike protein.

“I think it is super worrisome,” Dartmouth professor and Adagio co-founder and CEO Tillman Gerngross told Endpoints News this weekend. Moderna CEO Stéphane Bancel echoed similar concerns, telling the Financial Times that experts warned him, “This is not going to be good.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie’s Rinvoq.

As a result of a recent readout highlighting major adverse cardiac events (MACE), malignancy, mortality and thrombosis with Xeljanz a couple of months ago, AbbVie put out a notice late Friday afternoon that it is adding the new class risks to its label for their rival drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future.

The combined companies will now serve a wider range of drug research and development scientists, according to Albert Li, who founded IVAL in 2004 and is set to join the Discovery leadership team as the CSO of pharmacology and toxicology.

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

Three top biopharma companies are seeking more details from the FDA on how the agency conducts its benefit-risk assessments for new drugs and biologics.

While Pfizer, Amgen and Janssen praised the agency for further spelling out its thinking on the subject in a new draft guidance, including a discussion of patient experience data as part of the assessment, the companies said the FDA could’ve included more specifics in the 20-page draft document.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Re­searchers move clos­er to de­ci­pher­ing blood clots from As­traZeneca, J&J's Covid-19 vac­cines

Researchers may be nearing an answer for the mysterious and life-threatening blood clots that appeared on very rare occasions in people who received the J&J or AstraZeneca Covid-19 vaccine.

The new work builds on an early hypothesis researchers in Norway put forward last spring, when the cases first cropped up. They proposed the events were similar to blood clots that can occur in a small subset of patients who receive heparin, one of the most commonly used blood thinners.

Janet Woodcock (AP Images)

Janet Wood­cock plots her fu­ture at FDA, with se­nior ad­vi­sor role to fall back on if Califf wins con­fir­ma­tion

Acting FDA commissioner Janet Woodcock has been the face of just about every drug approval decision at the agency since the turn of the century. Since the pandemic began, she’s moved between the top of the drugs center to the head of therapeutics at Operation Warp Speed, leading the drive for work on Covid-targeted mAbs and antivirals.

Looking forward — and pending a quick Senate confirmation to cement Rob Califf’s return to the top of FDA early next year — Woodcock’s role at the agency will again be in flux.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.